A vaccine designed to battle breast cancer is moving to a randomized, Phase II clinical trial after an initial study showed it was safe and effective at targeting HER-2 positive cancers.

Anita Triolo participated in the Phase I study of the vaccine. She was diagnosed with breast cancer at the age of 42 in 2005.

"It's given me I think it's going on 17 years now [in remission]. So, it's given me a lot of extra time with my family," said Triolo. 

"I have very high hopes that it is close to the final step of this vaccine potentially becoming a treatment for patients with breast cancer," said lead author Dr. Mary "Nora" L. Disis, who's a professor of medicine at the University of Washington School of Medicine.

Learn more about the study in our news release. For more details about the research, visit the Cancer Vaccine Institute website.  The phase II trial is recruiting patients; contact the patient coordinator: uwcvi@uw.edu or 206-543-3829.

Download broadcast-ready soundbites and lab video showcasing the breast cancer vaccine.